Show simple item record

dc.contributor.authorOtero, Alejandra
dc.contributor.authorVázquez, María Ángeles
dc.contributor.authorSuárez, Francisco
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorPértega-Díaz, Sonia
dc.contributor.authorGómez, Manuel
dc.date.accessioned2022-06-13T07:55:49Z
dc.date.available2022-06-13T07:55:49Z
dc.date.issued2017-05-23
dc.identifier.citationOtero A, Vázquez MA, Suárez F, Margusino L, Pértega S, Gómez M. Paritaprevir-ritonavir, ombitasvir and dasabuvir plus ribavirin to treat hepatitis C genotype 1 infection after liver transplantation: a single-center experience. Glob Surg. 2017;3(3):1-5es_ES
dc.identifier.issn2396-7307
dc.identifier.urihttp://hdl.handle.net/2183/30887
dc.description.abstract[Abstract] Hepatitis C virus (HCV) infection is a disease with a significant worldwide impact. In Europe and the United States, chronic hepatitis C is the most common cause of chronic hepatic disease and the main indication for liver transplantation. Recurrent hepatitis C infection is universal among transplant recipients who have detectable viremia at the time of transplantation. Hepatitis C treatment was revolutionized with the introduction of safe, powerful direct action antivirals (DAA), which allow the use of multidrug combinations that can selectively inhibit the targets required for viral replication. One of these regimens combined paritarpevir [NS3/4A protease inhibitor], ombitasvir [NS5A inhibitor] and dasabuvir [NS5B polymerase inhibitor], plus ribavirin and was found to be highly effective (SVR rates of 97% in genotype 1). We report the results of a real-world clinical practice study in a single clinical unit in 22 liver graft recipients, transplanted due to cirrhosis caused by genotype 1 HCV with post-transplantation viral recurrence, who received ombitsavir combined with paritaprevir-ritonavir plus dasabuvir and ribavirin. We found an SVR rate at 12 weeks post-treatment of 100% and a remarkably low rate of adverse events. Conclusion: oral ombitasvir combined with ritonavir-paritaprevir plus dasabuvir and ribavirin for 24 weeks is a highly effective treatment for eliminating HCV in liver transplant recipients with genotype 1 and scant fibrosis, producing few serious adverse effects.es_ES
dc.language.isoenges_ES
dc.publisherOpen Access Textes_ES
dc.relation.urihttps://doi.org/10.15761/GOS.1000162es_ES
dc.rightsAtribución 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectHepatitis C viruses_ES
dc.subjectInfectiones_ES
dc.subjectLiver transplantationes_ES
dc.subjectSurgeryes_ES
dc.titleParitaprevir-ritonavir, ombitasvir and dasabuvir plus ribavirin to treat hepatitis C genotype 1 infection after liver transplantation: a single-center experiencees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleGlobal Surgeryes_ES
UDC.volume3es_ES
UDC.issue3es_ES
UDC.startPage1es_ES
UDC.endPage5es_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record